Microfluidic nanoparticle synthesis for oral solid dosage forms: a step toward clinical transition processes
Lucia Morelli,Evelyn Ochoa,Lucia Salvioni,Marco Davide Giustra,Beatrice De Santes,Francesca Spena,Linda Barbieri,Stefania Garbujo,Giulia Tomaino,Brian Novati,Leonardo Bolis,Saliha Moutaharrik,Davide Prosperi,Luca Palugan,Miriam Colombo
DOI: https://doi.org/10.1016/j.ijpharm.2024.123850
IF: 6.51
2024-01-28
International Journal of Pharmaceutics
Abstract:Nanomedicine provides various opportunities for addressing medical challenges associated with drug bioavailability, stability, and efficacy. In particular, oral nanoparticles (NPs) represent an alternative strategy to enhance the solubility and stability of active ingredients through the gastrointestinal tract. The nanocarriers could be used for both local and systemic targeting, enabling controlled release of encapsulated drugs. This approach allows more efficient therapies. In this work, we aim to develop reliable oral solid dosage forms incorporating NPs produced by either one pot synthesis or continuous production, following protocols that yield highly consistent outcomes, promoting their technology transfer and clinical use. Microfluidics technology was selected to allow an automated and highly productive synthetic approach suitable for the highly throughput production. In particular, innovative systems, which combine advantage of NPs and solid dosage formulation, were designed, developed, and characterized demonstrating the possibility to obtaining oral administration. The resulting NPs were thus carried on oral dosage forms, i.e., pellets and minitablets. NPs resulted stable after dosage forms manufacturing, leading to confidence also on protection of encapsulated drugs. Indomethacin was used as a tracer to test biopharmaceutical behaviour. Anti-inflammatories or cytotoxic chemotherapeutics could be vehiculated leading to a breakthrough in the treatment of severe diseases allowing the oral administration of these drugs. We believe that the advancement achieved with the results of our work paves the way for the progression of nanoproducts into clinical transition processes.
pharmacology & pharmacy